or Try an Advanced Search...

    Technical Analysis for PROK - ProKidney Corp.

    Grade Last Price % Change Price Change
    D 1.65 -8.33% -0.15
    PROK closed down 8.33 percent on Wednesday, November 20, 2024, on 43 percent of normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical PROK trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    MACD Bearish Signal Line Cross Bearish 0.00%
    180 Bearish Setup Bearish Swing Setup 0.00%
    Wide Bands Range Expansion 0.00%
    MACD Bearish Centerline Cross Bearish -8.33%
    Bullish Engulfing Bullish -8.33%
    Outside Day Range Expansion -8.33%
    Wide Bands Range Expansion -8.33%
    Wide Bands Range Expansion -0.30%
    200 DMA Resistance Bearish -2.65%
    Older End-of-Day Signals for PROK ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 20 hours ago
    20 DMA Resistance about 23 hours ago
    Down 5% about 23 hours ago
    Down 3% about 23 hours ago
    Down 2 % about 23 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    PROK Chart by TradingView
    Basic chart:

    Profile

    ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Life Sciences Health Sciences Pharmacy Cell Therapy FDA Kidney Disease Regenerative Medicine Breakthrough Therapy Chronic Kidney Disease Regenerative Medicine Advanced Therapy

    Is PROK a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 12 ProKidney GAAP EPS of -$0.14
    Nov 12 ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
    Nov 7 ProKidney: Major Catalyst Is Too Far Away
    Nov 5 ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
    Oct 22 Suvretta Capital Management's Strategic Acquisition in ProKidney Corp
    Oct 18 We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate
    Oct 14 ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
    Oct 9 ProKidney to Participate in the UBS Virtual Organ Restoration Day
    Sep 29 Wall Street Breakfast: The Week Ahead
    Sep 4 ProKidney drops Phase III CKD study to focus on US market and save up to $175m
    See more PROK news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.44
    52 Week Low 1.18
    Average Volume 760,518
    200-Day Moving Average 2.17
    50-Day Moving Average 1.90
    20-Day Moving Average 1.80
    10-Day Moving Average 1.92
    Average True Range 0.19
    RSI (14) 43.18
    ADX 20.5
    +DI 18.50
    -DI 26.61
    Chandelier Exit (Long, 3 ATRs) 1.69
    Chandelier Exit (Short, 3 ATRs) 2.06
    Upper Bollinger Bands 2.18
    Lower Bollinger Band 1.42
    Percent B (%b) 0.3
    BandWidth 42.03
    MACD Line -0.02
    MACD Signal Line -0.01
    MACD Histogram -0.0114
    Fundamentals Value
    Market Cap 112.01 Million
    Num Shares 67.9 Million
    EPS -0.58
    Price-to-Earnings (P/E) Ratio -2.84
    Price-to-Sales 0.00
    Price-to-Book 91.32
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.94
    Resistance 3 (R3) 1.96 1.88 1.89
    Resistance 2 (R2) 1.88 1.81 1.87 1.87
    Resistance 1 (R1) 1.77 1.77 1.73 1.75 1.86
    Pivot Point 1.69 1.69 1.68 1.68 1.69
    Support 1 (S1) 1.58 1.62 1.54 1.56 1.44
    Support 2 (S2) 1.50 1.58 1.49 1.43
    Support 3 (S3) 1.39 1.50 1.41
    Support 4 (S4) 1.37